Photo: Maddie Meyer/Getty Images
modern announced this Wednesday that it began the second-phase clinical trials of its vaccine for fight the omicron variant of covid-19.
The Massachusetts-based pharmaceutical company indicated that this phase of the study will include some 300 participants who have already received two doses of the vaccine and another 300 subjects with the full schedule and a booster dose.
Regarding the effectiveness of the current vaccine, Moderna indicated that according to a study, the neutralization of omicron six months after the third dose of 50 micrograms of the mRNA-1273 vaccine decreased, but remained detectable in all participants in the trial.
“We are reassured by the persistence of antibodies against omicron six months after the currently authorized booster of 50 micrograms of mRNA-1273”, stressed the chief executive of the pharmaceutical company, Stéphane Bancel, who highlighted the importance of a booster specifically targeting the omicron due to the long-term threat demonstrated by the variant of evading immune defenses.
According to data published by the journal The New England Journal of Medicine29 days after receiving the Moderna COVID-19 booster, there was up to a 6.3-fold decline in neutralization of the omicron variant from its maximum capacity, although antibodies were still detected in all participants. This neutralization only decreased 2.3 times when it came to the original strain of the virus.
Pfizer and BioNTech announced Tuesday the start of a clinical trial of a modified COVID-19 vaccine that could protect against the omicron variant of the coronavirus.
The statement from these two firms indicates that the initial results of the study, which will include 1,420 volunteers aged between 18 and 55, are expected to be available in the first half of this year.
“We continue to maintain an open dialogue with health authorities about an updated vaccine and ongoing data on the currently available vaccine, including what authorities require,” Pfizer said in a message.